Could a common pain reliever boost a cancer drug? early trial underway
NCT ID NCT04640779
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—selinexor and choline salicylate (a type of aspirin)—in 22 adults with certain lymphomas or multiple myeloma that had come back or not responded to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope that adding choline salicylate might allow a lower, less toxic dose of selinexor while still fighting the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
selinexor and choline salicylate
What this could lead to
If this combination works, it could offer a new treatment option for patients with certain lymphomas or multiple myeloma that have not responded to prior therapy.
What could go wrong
This is a very early phase 1 trial with only 22 participants, so it is mainly looking at safety and dosing, not yet proving effectiveness. The combination may cause side effects or may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States